Common Light Chain Antibody
Kyinno's Bispecific Antibody Platform with Common Light Chain Mice
To support the development of bispecific antibodies, Kyinno has successfully developed the Common Light Chain (KY-CLCTM) Mouse technology platform. The KY-CLC-mouse features no lambda (λ) light chain expression and fully identical kappa (κ) light chains, which offer excellent solubility and stability (protected by patent). KY-CLC-mouse enables rapid and efficient screening for high-affinity, highly specific antibodies against all validated targets. Bispecific antibodies assembled using this platform are comparable to monoclonal antibodies in terms of expression, purification, stability, and other critical attributes.
We welcome collaboration to explore the opportunities this platform provides.
Affinity tests of LAG3/PD1, PD-L1/EGFR, MET/EGFR bispecific antibodies：
1. LAG3/PD1 bispecific antibody
Binding affinities of bispecific antibody KA-1833 against PD1 and LAG3 to PD1-HIS and LAG3-HIS
2. Blocking activity of bispecific antibody KA-1833 against PD1 and LAG3
3. SEC-HPLC and SDS-PAGE
- Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
- Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. Review – Cancer Research. 28 September 2020